As expected intakes are below EFSA’s oral t-TDI (4 μg/kg bw), SCENIHR considered that BPA leaching from dental devices poses a negligible risk for human health. Based on estimated internal doses, though, “risk for adverse effects of BPA may exist” after non-oral administration (e.g. for implants, catheters and tubing), especially for neonates in intensive care, infants receiving prolonged treatments, and dialysis patients.
European Commission. Scientific Committee on Emerging and Newly Identified Health Risks. Opinion on the safety of the use of bisphenol A in medical devices. The SCENIHR adopted this opinion by written procedure on 18 February 2015. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_040.pdf
The above items were taken from the April 2015 issue of Toxicology and Regulatory News which is sent automatically to members of bibra (click here)News Home Guest Write For Us? Contact Us